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Clinical Significance of Extraintestinal Hafnia alvei Isolates from 61 Patients and
Review of the Literature
Huldrych Giinthard and Andreas Pennekamp From the Department ofInternal Medicine, Stadtspital Triemli, and the
Department ofMedical Microbiology of the University ofZurich,
Zurich, Switzerland
Hafnia alvei is a gram-negative bacterium that is rarely isolated from human specimens and is
rarely considered to be pathogenic. It has been associated with gastroenteritis, meningitis, bacter-
emia, pneumonia, nosocomial wound infections, endophthalmitis, and a buttock abscess. We studied
80 H. alvei isolates recovered from 61 patients within a period of 30 months. H. alvei was cultured
from sites that included the respiratory tract (n = 38), the gastrointestinal tract (n = 16), and the
urogenital tract (n = 12); the organism was found in blood cultures (n = 8), on central venous
catheters (n = 3), and on the skin (n = 3). Only 25% of H. alvei isolates were recovered in pure
cultures. Fifty-seven (93.4%) of the patients had an underlying illness. H. alvei proved to be the
etiologic agent in two episodes of septicemia and in one episode of peritonitis and was probably
responsible for septicemia in two other patients and pneumonia in one. All six of these patients
recovered after receiving antibiotic treatment and/or standard surgical treatment, when needed.
Three of these infections were nosocomial, and three were community acquired. Of the strains of
H. alvei tested in our study, 100% were susceptible to netilmicin, ciprofloxacin, and imipenem; 92%
were susceptible to piperacillin; 90% were susceptible to co-trimoxazole; and 88% were susceptible
to ceftriaxone and ceftazidime. In this study, we found H. alvei to be a rare but significant etiologic
agent of nosocomial and community-acquired infections.
Hafnia alvei is a gram-negative facultative rod-shaped anaer-
obe that belongs to the Enterobacteriaceae; the organism was
formerly named Enterobacter hafniae. H. alvei is rarely consid-
ered to be pathogenic; rather, H alvei has been found to be
related to the enteropathogenic Escherichia coli on the basis
of a single virulence factor. Electron microscopy has demon-
strated inflammation and mucosal invasion by H alvei in rabbit
bowels, and an attachment-effacement gene like that detected
in enteropathogenic E. coli was found in H. alvei by hybridiza-
tion [1, 2]. No other distinct virulence factors have been noted
in this organism so far [3]. Stool specimens are generally not
examined for the presence of H alvei.
Cases of diarrhea due to H alvei have occurred mainly in
children. H. alvei was reported to have caused acute gastroen-
teritis in children from Bangladesh and Spain [1-2]. In one
study, 16% of Finnish tourists with acute gastroenteritis and
diarrhea who were returning from Morocco excreted H alvei
in their stools [4]. Seven strains isolated from children with
diarrhea expressed the attachment-effacement gene [2]. In two
case reports, H alvei was mentioned as a cause of nonbloody
diarrhea. One of these cases was presumably associated with
reactive arthritis [5, 6]; however, cultures of joint aspirates
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were negative. A single case of H alvei meningitis in a 1-
year-old girl [7] and a case of necrotizing H alvei enterocolitis
with septicemia in a 20-day-old boy [8] have also been de-
scribed. In adults, H alvei has caused bacteremia [9, 10], pneu-
monia, and nosocomial wound infections [11-13]. H. alvei
was recovered with Salmonella arizonae from a patient with
endogenous endophthalmitis who was receiving steroids [14].
Recently, H alvei was isolated from a buttock abscess that
resulted from skin puncture with carpet nails in an otherwise
healthy middle-aged man [15].
Until now, there have been no data published about the true
rate of isolation of H. alvei from clinical specimens, and the
clinical significance of this bacterium remains to be defined.
Therefore, we performed a study on the frequency of isolation
of H alvei from clinical specimens (except stools) and corre-
lated the microbiological findings with the clinical data.
Materials and Methods
Patient evaluation. Patients from whom isolates ofH. alvei
were recovered during routine diagnostic testing at the Depart-
ment of Medical Microbiology, University of Zurich (Zurich)
and at the Microbiology Laboratory of the Stadtspital Triemli
(Zurich) between January 1992 and May 1995 were identified
by reviewing the laboratories' records. The patients' charts
were reviewed for data on isolation sites, underlying illnesses,
cocultivation of other bacteria, and discrimination between
nosocomial infections or community-acquired infections.
Isolation and identification. H. alvei was isolated from nor-
mally sterile body fluids such as blood, ascitic fluid, and ab-
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dominal aspirates as well as from postoperative indwelling
catheters, central venous lines, and urine collected from cathe-
ters. Respiratory tract isolates were cultured from sputum and
tracheal and bronchial aspirates. Samples other than blood were
plated on selective and differential media, and colonies of En-
terobacteriaceae were detected on MacConkey agar (Becton
Dickinson, Basel, Switzerland); blood was cultured with use
of the BacT/Alert blood culture system (Organon Teknika,
Basel).
The identification of Enterobacteriaceae was based on bio-
chemical data obtained by means of commercial identification
systems (API20E and RapID 32E; bioMerieux, Geneva, Swit-
zerland) and on lack of lactose fermentation on MacConkey
agar. Biochemical reactions for which H. alvei was positive
included lysine decarboxylase, ornithine decarboxylase, and
mannitol fermentation, whereas it was negative for fermenta-
tion of sorbitol, inositol, sucrose, and melibiose; these negative
reactions differentiated H. alvei from Enterobacter aerogenes.
Strains with T values of <0.50 and probabilities of identifica-
tion of <90% in one of the commercial systems were excluded
from the study.
Antimicrobial susceptibility testing. Bacteria were tested
for susceptibility by the disk diffusion method according to the
National Committee for Clinical Laboratory Standards
(NCCLS) guidelines. Strains were interpreted as susceptible,
intermediately susceptible, or resistant on the basis of the
NCCLS criteria. Susceptibilities were compared with use ofthe
X2 test. Strains that were susceptible to ampicillin, amoxicillin/
clavulanic acid, and cephalothin are most likely not part of the
genus Hafnia [16] and thus were excluded from the study. We
excluded strains of Salmonella and Enterobacter (one each),
which were misidentified as H alvei by the commercial sys-
tems, by means of these procedures.
We conducted a MEDLINE search with use of the terms
Hafnia alvei and Enterobacter hafnia. All reports indexed from
December 1966 to August 1995 were evaluated if they pre-
sented clinically important information.
Results
Within the 30-month study period H. alvei was isolated from
80 samples collected from 61 patients. Twenty ofthese patients
were female, and 41 were male. The mean age for all patients
was 55.4 years (range, 13-81 years); the mean age for women
was 61.8 years, and that for men was 53.5 years. H alvei was
cultured from the respiratory tract 38 times for 35 patients
(57.4%), from the gastrointestinal tract 16 times for nine pa-
tients (14.8%), and from the urogenital tract 12 times for seven
patients (11.5%). The organism was isolated from eight blood
cultures of seven patients (11.5%), from three central venous
catheters of three patients (3.8%), and from the skin of three
patients (3.8%). Table 1 shows the sites of isolation ofH alvei,
which was isolated in pure culture of only 20 samples (25%).
Organisms cultured concomitantly with H alvei were Entero-
bacteriaceae, staphylococci, streptococci, and yeasts. None of
these microorganisms showed a predilection for association
with H. alvei (data not shown).
H. alvei was isolated from 57 patients (93.4%) with underly-
ing illnesses. Twenty (33%) ofthese patients had malignancies:
six had leukemia or lymphoma, seven had carcinomas of the
abdomen, five had carcinomas of the throat and bronchi, one
had a sarcoma, and one had an endometrial carcinoma. Abdom-
inal surgery was performed on 11 (18%) ofthe 61 patients; nine
(14.8%) were hospitalized because of trauma; nine (14.8%)
underwent heart surgery; four (6.6%) had acute or chronic
pancreatitis; three (4.9%) had chronic obstructive pulmonary
disease; and one (1.6%) underwent lung transplantation. An
underlying disease was not detected in four patients (6.6%).
Table 2 shows the isolation sites of H. alvei among patients
with underlying illnesses. Eighteen of 35 respiratory isolates
were from intubated patients; almost all respiratory isolates
from patients who had undergone cardiac surgery (seven of
eight isolates) or who were hospitalized because of trauma
(four of five isolates) were recovered from intubated patients.
None of the patients who had undergone abdominal surgery
had isolates of H alvei recovered from respiratory specimens.
Overall, 40 patients (66%) infected with H. alvei were intu-
bated, and 19 of them had H. alvei isolated from the respiratory
tract.
H. alvei was found to be the sole etiologic agent of invasive
disease in three (4.9%) of the 61 patients; two had septicemia
due to this organism, and one had peritonitis. All three patients
recovered after receiving treatment with imipenem/cilastatin.
The clinical characteristics of these three cases are displayed
in table 3. H. alvei, together with other organisms, was possibly
responsible for two other cases of septicemia and a case of
pneumonia.
Ten additional patients in our review received adequate anti-
biotic coverage for H. alvei, but it was not possible to prove
in retrospect that the organism had caused clinically significant
infection.
A comparison of the results of antimicrobial susceptibility
testing of our strains and those from patients described pre-
viously is shown in table 4. The H alvei strains tested in our
study were all susceptible to netilmicin and ciprofloxacin; 99%
were susceptible to imipenem and tobramycin; 92% to pipera-
cillin; 90% to co-trimoxazole; 89% to piperacillin/tazobactam;
and 88% each to ceftriaxone and ceftazidime.
Discussion
H alvei is rarely considered to be a pathogenic organism.
In recent years, case reports of various infections due to
H. alvei have been published [1-15, 17, 18]. In our retrospec-
tive 30-month study, H. alvei was recovered in 80 specimens
from 61 patients. The majority of these patients (93.4%) had
a severe underlying condition; this finding supports other re-
ports that H alvei is primarily isolated from patients with
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Table 1. Isolation of Hafnia alvei in pure or mixed cultures of specimens from different body sites
of 61 patients.
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Site involved
Respiratory tract*
Gastrointestinal tractt
Blood
Central venous catheter
Urogenital tractt
Skin
No. of isolates recovered
in pure cultures
8
5
3
1
3
o
No. of isolates recovered
in mixed cultures
30
11
5
2
9
3
Total no. (%) from indicated
site (n = 80)
38 (47.5)
16 (20)
8 (10)
3 (3.75)
12 (15)
3 (3.75)
NOTE. Twenty (25%) of the isolates were recovered in pure cultures, and 60 (75%) of the isolates were recovered
in mixed cultures.
* The following specimens were obtained: tracheal aspirates (16), pharyngeal smears (4), bronchoalveolar lavage
fluid (2), nasal smears (1), bronchial aspirates (7), and sputum (8).
t The following specimens were obtained: ascitic fluid aspirates (2), gallbladder (1), abscesses and deep abdominal
wounds (10), and pancreatic pseudocysts (3); no stool samples were included.
t The following specimens were obtained: urine collected from indwelling catheters (6), clean-catch urine (3),
scrotal smears (2), and episiotomy wound (1).
underlying illnesses [11-12], except when it is an enteric
pathogen [1, 4-6, 8, 17].
Thirty-eight H alvei isolates were recovered from respira-
tory specimens, 16 were recovered from the gastrointestinal
tract, 12 were recovered from the urogenital tract, eight were
recovered from blood, three were recovered from intravenous
catheters, and three were recovered from the skin. Only 25%
of all H. alvei isolates grew in pure culture. H. alvei was
cultured with a variety ofother bacteria and fungi in the respira-
tory and gastrointestinal specimens.
H. alvei was the only identified pathogen causing two cases
of septicemia and one case of acute peritonitis. The peritonitis
occurred after a patient with stenosis of the choledochus duct
underwent endoscopic retrograde cholangiopancreatography,
and H. alvei was isolated from his blood and peritoneal fluid.
This circumstance indicates that the bacterium's portal of entry
Table 2. Isolation of Hafnia alvei from different body sites of 61 patients with and without underlying conditions.
Site involved
Underlying conditions
Malignancies
Leukemia or lymphoma
Abdominal carcinoma
Throat or bronchial carcinoma
Others
Totalt
Abdominal surgeryt
Trauma§
Heart surgery II
Pancreatitis
Chronic obstructive pulmonary disease
Lung transplantation
None
Respiratory
tract*
4/1
3/1
1/0
5/4
8/7
2/2
2/0
1/1
4/0
Gastrointestinal
tract
2
4
6
Blood and central
venous catheter
2
2
Urogenital
tract
2
1
1
2
1
1
Skin Total (%)
6
7
5
2
20 (33)
11 (18)
9 (14.8)
9 (14.8)
4 (6.6)
3 (4.9)
1 (1.6)
4 (6.6)
NOTE. Only one isolate per patient was taken into account. Of the 61 patients, 35 (18 of whom were intubated) had isolates recovered from the respiratory
tract; nine, from the gastrointestinal tract; seven, from blood and central venous catheters; seven, from the urogenital tract; and three, from the skin.
* Total no. of isolates/no. of isolates from intubated patients.
t Includes carcinoma (13 patients), acute myelocytic leukemia (3), plasmocytoma (1), non-Hodgkin's lymphoma (1), sarcoma (1), and aplastic anemia of
unknown etiology (1).
t Includes incarcerated hernia (3 patients), perforation of the sigmoid colon (2), small bowel ileus (2), infrarenal aortic aneurysm (2), intra-abdominal abscess
(2), delivery of infant by vacuum extraction (1), and endoscopic retrograde cholangiopancreatography (1).
§ Includes subarachnoidal bleeding (3 patients), polytrauma (2), knife injuries (2), bums (1), femur fracture (1).
II Includes aortocoronary bypass surgery (8 patients) and aortic valve replacement (1).
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Table 3. Clinical characteristics of patients with Hafnia alvei infection.
First day
Type of organism isolated Antibiotic treatment,
Age (y)/sex infection Site(s) involved after admission Underlying disease Clinical presentation outcome*
371M Septicemia Blood (X2),t pancreatic 38 Acute pancreatitis Pancreatic pseudocysts, Imipenemlcilastatin,
pseudocyst fluid perforation of transverse recovered
colon, sepsis syndrome
49/F Septicemia Blood (X2),t central 28 Sigmoid diverticulitis Perforation of the sigmoid colon Imipenemlcilastatin,
venous catheter with sepsis syndrome recovered
501M Peritonitis Peritoneal fluid Chronic pancreatitis Stenosis of the choledochus duct, Imipenemlcilastatin,
acute abdomen recovered
* The surgical treatment in these cases is not included because standard procedures were performed; no surgical interventions were primarily done for infection with
H. alvei.
t Organism isolated in two separate blood cultures.
might have been the gastrointestinal tract, where it is consid-
ered to be a commensal [16]. Earlier reports have also men-
tioned a correlation between abdominal wounds or abdominal
surgery and the isolation of H alvei in blood [10]. H alvei
was isolated along with other pathogens from three other pa-
tients who had septicemia, pneumonia, and cholangitis.
Overall, 11.5% of the patients in our study population had
proven (or at least probable) infections caused by H alvei, and
57 of them presented with an underlying illness. Of six patients
with H. alvei infections, three had nosocomial infections [19],
and three had community-acquired infections. The number of
infections might even have been higher, but the retrospective
nature of our study did not allow correlation of the other
H alvei isolates with clinically significant infections. However,
10 additional patients from whom H. alvei was isolated were
treated with broad-spectrum antibiotics in the absence of a
clear diagnosis of infection. This circumstance supports the
hypothesis that there was a higher rate of significant infections
in our study population. In all six of our patients with proven
or probable H. alvei infections, the infections were successfully
treated with antibiotics chosen according to the results of sus-
ceptibility testing.
Table 4. Antimicrobial susceptibility test results for Hafnia alvei isolates.
Present report Literature reviewt
No. of strains Percent No. of strains Percent
Antibiotic tested susceptible* tested susceptible
Amoxicillinlclavulanic acid 77 1 NA NA
Ampicillin 76 9 23 9
Cephalothin 77 a 23 17
Cefamandole 71 79 NA NA
Ceftriaxone 73 88 NA NA
Ceftazidime 73 88 12 42
Cefuroxime 69 77 NA NA
Gentamicin NA NA 23 100
Amikacin NA NA 13 100
Netilmicin 75 100 NA NA
Tobramycin 73 99 NA NA
Ciprofloxacin 75 100 7 100
Piperacillin 64 92 13 85
Tetracycline NA NA 5 84
Piperacillinltazobactam 19 89 NA NA
Trimethoprim-sulfamethoxazole 76 90 13 92
Imipenemlcilastatin 73 99 8 100
Colistin 72 75 NA NA
NOTE. NA = not available.
* Susceptibility testing was performed according to the National Committee for Clinical Laboratory Standards
(NCCLS) for the disk diffusion method and interpreted according to NCCLS guidelines.
tData are from [6,16-19].
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As shown in table 1, 38 (47.5%) of all isolates recovered
from 35 patients were of respiratory origin. Eighteen of the
patients were intubated at the time that samples were obtained,
and 17 were not intubated during their hospital courses. Intu-
bated patients who are immunosuppressed as a result of cardiac
surgery or trauma seem to harbor H. alvei in their respiratory
tracts more often than do patients who have previously under-
gone abdominal surgery. Whether the oropharyngeal-tracheal
regions of these patients had been colonized previously or
whether they became colonized as a result of hospital proce-
dures (e.g., intubation) cannot be answered sufficiently. We
do not know the prevalence of H. alvei colonization of the
oropharyngeal-tracheal regions and other bodily sites in healthy
persons or patients with underlying diseases. In large studies
[20-21], this bacterium was rarely recovered from any site,
making nosocomial infection improbable and emphasizing the
likelihood of endogenous colonization in most patients before
admission to the hospital.
On the other hand, only eight of 30 respiratory tract isolates
were recovered from pure cultures, compared with 22 isolates
that were recovered from mixed cultures; these mixed cultures
mainly consisted of other gram-negative bacteria that are
known to colonize the oropharyngeal-tracheal tract in severely
ill patients [22]. The presence of H. alvei in feces reflects the
fact that the organism is part of the normal bowel flora. Case
reports of H. alvei as the etiologic agent of diarrhea must be
evaluated critically because no toxin production or toxic muco-
sal changes in humans have been detected so far. However,
it is worth mentioning that H. alvei might cause diarrhea in
immunocompromised patients, as case reports of neonates and
malnourished children with diarrhea have shown [1, 7, 17].
In comparing the susceptibilities of H. alvei isolates, we
observed a higher rate of susceptibility to ampicillinJamoxicil-
lin and cephalothin among the strains described in the literature.
In conducting this study we used susceptibility to amoxicillin
and first-generation cephalosporins as selection criteria; there-
fore, these data are not comparable to those from previous
reports.
In our study the most active antimicrobials were netilmicin
(100% of isolates were susceptible), ciprofloxacin (100% sus-
ceptible), and imipenem (99% susceptible). These results are
similar to the scant results reported in the literature (only a
few strains have been tested), where 100% of the H. alvei
strains were found to be susceptible to amikacin, gentamicin,
ciprofloxacin, and imipenem [23 - 26].
The susceptibility to ceftazidime observed in our study was
significantly different from that reported in the literature (P <
.001). This difference cannot be explained but is probably not
caused by the larger number of strains tested in our study
because the results were otherwise almost congruent. Another
slight difference was observed when susceptibilities to pipera-
cillin were compared: 92% of our strains (64 tested) were
susceptible, while 85% of strains in other reports (13 tested)
were susceptible. However, the fact that susceptibility results
from other reports as well as from our study were comparable
for most antimicrobials and that the biochemical features were
similar indicates that H. alvei was correctly identified as the
pathogen.
In summary, this study shows that H. alvei is a rare human
pathogen; however, the organism may be responsible for seri-
ous nosocomial and community-acquired infections. Infections
mainly occur in patients with underlying illnesses, and H. alvei
is often isolated in coculture with different gram-negative rods,
which may be due to endogenous colonization of the bowel.
Treatment of H. alvei infection on the basis of antimicrobial
susceptibility testing results is effective. In severe cases, treat-
ment with imipenem or a third-generation cephalosporin in
combination with an aminoglycoside is recommended. More
data on the role of H. alvei and its pathogenicity are needed.
In addition, the colonizing rate for this organism in different
sites in healthy adults must be determined.
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